BaghdadliA, PascalC, GrisiS, AussillouxC: Risk factors for self injurious behaviours among 22 young children with autistic disorders. J Intellect Disabil Res, 5:622–627, 2003.
5.
BakerDA, XiZX, ShenH, SwansonCJ, KalivasPW: The origin and neuronal function of in vivo nonsynaptic glutamate. J Neurosci, 22:9134–9141, 2002.
6.
BerksonG: Repetitive stereotyped behaviors. Am J Ment Defic, 88:239–246, 1983.
7.
BlochMH, PanzaKE, GrantJE, PittengerC, LeckmanJF: N-acetylcysteine in the treatment of pediatric trichotillomania: a randomized, double-blind, placebo-controlled add-on trial. J Am Acad Child Adolesc Psychiatry, 52:231–240, 2013.
8.
BlochMR, ElliottM, ThompsonH, KoranLM. Fluoxetine in pathologic skin-picking: Open-label and double-blind results. Psychosomatics, 42:314–319, 2001.
9.
BodfishJW, LewisMH: Epidemiology of self-injurious behavior in mental retardation: A review. In: Self-injurious behavior: Gene–brain–behavior relationships. Edited by SchroederS.R., Oster–GraniteM.L., ThompsonT.. Washington, DC: American Psychological Association, 23–39, 2002.
10.
CampbellM, AndersonLT, SmallAM, AdamsP, GonzalezNM, ErnstM: Naltrexone in autistic children: Behavioral symptoms and attentional learning. J Am Acad Child Adolesc Psychiatry, 32:1283–1291, 1993.
11.
DeanO, GiorlandoF, BerkM: N-acetylcysteine in psychiatry: current therapeutic evidence and potential mechanisms of action. J Psychiatry Neurosci, 36:78–86, 2011.
12.
DebS: Self-injurious behaviour as part of genetic syndromes. Br J Psychiatry, 172:385–388, 1998.
13.
DevlinS, HealyO, LeaderG, HughesBM: Comparison of behavioral intervention and sensory-integration therapy in the treatment of challenging behavior. J Autism Dev Disord, 41:1303–1320, 2011.
14.
DuerdenEG, OatleyHK, Mak-FanKM, McGrathPA, TaylorMJ, SzatmariP, RobertsSW: Risk factors associated with self-injurious behaviors in children and adolescents with autism spectrum disorders. J Autism Dev Disord, 5:2460–2470, 2012.
15.
DykensEM, KasariC: Maladaptive behavior in children with Prader–Willi syndrome, Down syndrome, and nonspecific mental retardation. Am J Ment Retard, 102:228–237, 1997.
16.
GhanizadehA, DerakhshanN: N-acetylcysteine for treatment of autism, a case report. J Res Med Sci, 17:985–987, 2012.
17.
GrantJE, OdlaugBL, KimSW: N-acetylcysteine, a glutamate modulator, in the treatment of trichotillomania: A double-blind, placebo-controlled study. Arch Gen Psychiatry, 66:756–763, 2009.
18.
HardanAY, FungLK, LiboveRA, ObukhanychTV, NairS, HerzenbergLA, FrazierTW, TirouvanziamR: A randomized controlled pilot trial of oral N-acetylcysteine in children with autism. Biol Psychiatry, 71:956–961, 2012.
19.
HilleryJ, DoddP: Self-injurious behaviour. In: Psychiatric and Behavioural Disorders in Intellectual and Developmental Disabilities, 2nd ed. Edited by BourasN., HoltG.. Cambridge: Cambridge University Press, 225–237, 2007.
20.
JaselskisCA, CookEHJr, FletcherKE, LeventhalBL: Clonidine treatment of hyperactive and impulsive children with autistic disorder. J Clin Psychopharmacol, 12:322–327, 1992.
21.
JohnsonNL, RodriguezD: Children with autism spectrum disorder at a pediatric hospital: A systematic review of the literature. Pediatr Nurs, 39:131–141, 2013.
22.
KingBH: Pharmacological treatment of mood disturbances, aggression, and self-injury in persons with pervasive developmental disorders. J Autism Dev Disord. 30:439–445, 2000.
23.
KingBH, HollanderE, SikichL, McCrackenJT, ScahillL, BregmanJD, DonnellyCL, AnagnostouE, DukesK, SullivanL, HirtzD, WagnerA, RitzL: STAART Psychopharmacology Network. Lack of efficacy of citalopram in children with autism spectrum disorders and high levels of repetitive behavior: citalopram ineffective in children with autism. Arch Gen Psychiatry. 66:583–590, 2009.
LangR, DiddenR, MachalickW, RispoliM, SigafoosJ, LancioniG, MulloyA, RegesterA, PierceN, KangS: Behavioral treatment of chronic skin-picking in individuals with developmental disabilities: A systematic Review. Res Dev Disabil, 31:304–315, 2010.
26.
MacyJDJr, BeattieTA, MorgensternSE, ArnstenAF: Use of guanfacine to control self-injurious behavior in two rhesus macaques (Macaca mulatta) and one baboon (Papio anubis). Comp Med, 50:419–425, 2000.
27.
MarcusRN, OwenR, KamenL, ManosG, McQuadeRD, CarsonWH, AmanMG: A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. J Am Acad Child Adolesc Psychiatry. 48:1110–1119, 2009.
28.
MatsonJL, CooperC, MaloneCJ, MoskowSL: The relationship of self-injurious behavior and other maladaptive behaviors among individuals with severe and profound intellectual disability. Res Dev Disabil, 29:141–148, 2008.
29.
McCrackenJT, McGoughJ, ShahB, CroninP, HongD, AmanMG, ArnoldLE, LindsayR, NashP, HollwayJ, McDougleCJ, PoseyD, SwiezyN, KohnA, ScahillL, MartinA, KoenigK, VolkmarF, CarrollD, LancorA, TierneyE, GhumanJ, GonzalezNM, GradosM, VitielloB, RitzL, DaviesM, RobinsonJ, McMahonD, Research Units on Pediatric Psychopharmacology Autism Network: Risperidone in children with autism and serious behavioral problems. N Engl J Med, 347:314–321, 2002.
30.
McDougleCJ, KreschLE, PoseyDJ: Repetitive thoughts and behavior in pervasive developmental disorders: treatment with serotonin reuptake inhibitors. J Autism Dev Disord. 30:427–435, 2000.
31.
McDougleCJ, ScahillL, AmanMG, McCrackenJT, TierneyE, DaviesM, ArnoldLE, PoseyDJ, MartinA, GhumanJK, ShahB, ChuangSZ, SwiezyNB, GonzalezNM, HollwayJ, KoenigK, McGoughJJ, RitzL, VitielloB: Risperidone for the core symptom domains of autism: results from the study by the autism network of the research units on pediatric psychopharmacology. Am J Psychiatry, 162:1142–1148, 2005.
32.
MinshawiNF: Behavioral assessment and treatment of self-injurious behavior in autism. Child Adolesc Psychiatr Clin N Am., 17:875–886, x, 2008.
33.
MoranMM, McFarlandK, MelendezRI, KalivasPW, SeamansJK: Cystine/glutamate exchange regulates metabotropic glutamate receptor presynaptic inhibition of excitatory transmission and vulnerability to cocaine seeking. J Neurosci, 25:6389–6393, 2005.
34.
NyhanWL, WongDF: New approaches to understanding Lesch–Nyhan disease. N Engl J Med., 334:1602–1604, 1996.
35.
OdlaugBL, GrantJE: N-acetyl cysteine in the treatment of grooming disorders. J Clin Psychopharmacol, 27:227–229, 2007.
36.
OliverC, RichardsC: Self-injurious behavior in people with intellectual disability. Curr Opin Psychiatry, 23:412–416, 2010.
37.
OwenR, SikichL, MarcusRN, Corey–LisleP, ManosG, McQuadeRD, CarsonWH, FindlingRL: Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics, 124:1533–1540, 2009.
38.
PolitteLC, McDougleCJ: Atypical antipsychotics in the treatment of children and adolescents with pervasive developmental disorders. Psychopharmacology (Berl)Apr4. [Epub ahead of print], 2013.
39.
PoseyDJ, PuntneyJI, SasherTM, KemDL, McDougleCJ: Guanfacine treatment of hyperactivity and inattention in pervasive developmental disorders: a retrospective analysis of 80 cases. J Child Adolesc Psychopharmacol, 14:233–241, 2004.
40.
RanaF, GormezA, VargheseS: Pharmacological interventions for self-injurious behaviour in adults with intellectual disabilities. Cochrane Database Syst Rev., 4:CD009084, 2013.
41.
RichardsC, OliverC, NelsonL, MossJ: Self-injurious behaviour in individuals with autism spectrum disorder and intellectual disability. J Intellect Disabil Res., 56:476–489, 2012.
42.
RichmanDM, Barnard–BrakL, BoschA, ThompsonS, GrubbL, AbbyL: Predictors of self-injurious behaviour exhibited by individuals with autism spectrum disorder. J Intellect Disabil Res., 57:429–439, 2013.
43.
RojahnJ: Epidemiology and topographic taxonomy in self-injurious behavior. In: Destructive Behavior in Developmental Disabilities: Diagnosis and Treatment. Edited by ThompsonT., GrayD.B.. Thousand Oaks, CA: Sage Publications, 49–67, 1994.
44.
RojahnJ, EsbensenAJ.Epidemiology of self-injurious behavior in mental retardation: A review. In: Self-Injurious Behavior: Gene-Brain-Behavior Relationships., Edited by SchroederS.R., Oster–GraniteM.L., ThompsonT.. Washington, DC: American Psychological Association, 41–77, 2002.
45.
RuedrichSL, SwalesTP, RossvanesC, DianaL, ArkadievV, LimK: Atypical antipsychotic medication improves aggression, but not self-injurious behaviour, in adults with intellectual disabilities. J Intellect Disabil Res, 52(Pt 2):132–140, 2008.
46.
ScahillL, AmanMG, McDougleCJ, McCrackenJT, TierneyE, DziuraJ, ArnoldLE, PoseyD, YoungC, ShahB, GhumanJ, RitzL, VitielloB: A prospective open trial of guanfacine in children with pervasive developmental disorders. J Child Adolesc Psychopharmacol, 16:589–598, 2006.
47.
SheaS, TurgayA, CarrollA, SchulzM, OrlikH, SmithI, DunbarF: Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics, 114:e634–41, 2004.
48.
SimeonD, SteinDJ, GrossS, IslamN, SchmeidlerJ, HollanderE: A double-blind trial of fluoxetine in pathologic skin picking. J Clin Psychiatry, 58:341–347, 1997.
49.
SooryaL, KiarashiJ, HollanderE: Psychopharmacologic interventions for repetitive behaviors in autism spectrum disorders. Child Adolesc Psychiatr Clin N Am, 17:753–771, viii, 2008.
50.
SymonsFJ, ClarkRD, HattonDD, SkinnerM, BaileyDBJr: Self-injurious behavior in young boys with fragile X syndrome. Am J Med Genet A, 118A:115–121, 2003.
51.
SymonsFJ, SperryLA, DropikPL, BodfishJW: The early development of stereotypy and self-injury: a review of research methods. J Intellect Disabil Res., 49:144–158, 2005.
52.
SymonsFJ, ThompsonA, RealmutoG: Clonidine for self-injurious behavior. J Am Acad Child Adolesc Psychiatry, 43:1324–1325, 2004.
53.
Willemsen–SwinkelsSH, BuitelaarJK, NijhofGJ, van EnglandH: Failure of naltrexone hydrochloride to reduce self-injurious and autistic behavior in mentally retarded adults. Double-blind placebo-controlled studies. Arch Gen Psychiatry. 52:766–773, 1995.